Multiple myeloma

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Aktas Samur A, Corre J, Talluri S, …, Szalat R, …, Samur MK

Journal of Clinical Oncology44(4):321-334DOI: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaPubMed: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Tailoring Therapy for Frail and Elderly Myeloma Patients

George T, Szalat RE

The Cancer Journal32(5)DOI: Tailoring Therapy for Frail and Elderly Myeloma PatientsPubMed: Tailoring Therapy for Frail and Elderly Myeloma Patients

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

Fulciniti M, Yao Y, Perini T, …, Szalat R, …, Munshi NC

Blood Cancer Discovery7(1):129-141DOI: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3PubMed: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

Neighborhood disadvantage and multiple myeloma incidence in the Black Women’s Health Study

Holder EX, Szalat R, Palmer JR, Bertrand KA

International Journal of Epidemiology54(6)DOI: Neighborhood disadvantage and multiple myeloma incidence in the Black Women’s Health StudyPubMed: Neighborhood disadvantage and multiple myeloma incidence in the Black Women’s Health Study

Body size and risk of multiple myeloma in the Black Women’s Health Study

Kataria Y, Pillalamarri BN, Zirpoli G, Szalat R, Palmer JR, Bertrand KA

British Journal of Cancer130(5):830-835DOI: Body size and risk of multiple myeloma in the Black Women’s Health StudyPubMed: Body size and risk of multiple myeloma in the Black Women’s Health Study

Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes

Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur MK, Munshi NC

Nature Communications15(1)DOI: Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changesPubMed: Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes

Deciphering racial disparities in multiple myeloma outcomes

Bertrand KA, Szalat R

Blood Advances8(1):234-235DOI: Deciphering racial disparities in multiple myeloma outcomesPubMed: Deciphering racial disparities in multiple myeloma outcomes

Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis

Abdallah M, Arters F, Patel J, …, Szalat R

Blood Advances8(23):5935-5938DOI: Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosisPubMed: Febrile neutropenia in patients with Duffy-null–associated neutrophil counts and multiple myeloma or AL amyloidosis

Role of minimal residual disease assessment in multiple myeloma

Szalat R, Anderson K, Munshi N

Haematologica109(7):2049-2059DOI: Role of minimal residual disease assessment in multiple myelomaPubMed: Role of minimal residual disease assessment in multiple myeloma

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Samur MK, Roncador M, Aktas Samur A, …, Szalat R, …, Munshi NC

Blood141(14):1724-1736DOI: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaPubMed: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises

Samur MK, Szalat R, Munshi NC

BloodDOI: Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and PromisesPubMed: Single-Cell Profiling in Multiple Myeloma: Insights, Problems, and Promises

Prevalence of monoclonal gammopathy of undetermined significance in US black women

Bertrand KA, Zirpoli G, Pillalamarri BN, Szalat R, Palmer JR, Kataria Y

American Journal of Hematology97(9)DOI: Prevalence of monoclonal gammopathy of undetermined significance in US black womenPubMed: Prevalence of monoclonal gammopathy of undetermined significance in US black women

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan H, Szalat R

The Application of Clinical GeneticsVolume 14:241-254DOI: Genetic Predictors of Mortality in Patients with Multiple MyelomaPubMed: Genetic Predictors of Mortality in Patients with Multiple Myeloma

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi AH, Avet-Loiseau H, Szalat R, …, Samur MK

Blood138(20):1980-1985DOI: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WMPubMed: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Fillmore NR, Cirstea D, Munjuluri A, …, Szalat RE, Munshi NC

Blood Advances5(18):3511-3514DOI: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA studyPubMed: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, …, Szalat R, …, Gallardo M

Cancers13(13):3189DOI: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaPubMed: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Genomic Instability in Multiple Myeloma

Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ

Trends in Cancer6(10):858-873DOI: Genomic Instability in Multiple MyelomaPubMed: Genomic Instability in Multiple Myeloma

Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma

Alagpulinsa DA, Kumar S, Talluri S, …, Szalat R, …, Munshi NC

Blood Advances3(23):3968-3972DOI: Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myelomaPubMed: Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura F, Bolli N, Angelopoulos N, …, Szalat R, …, Campbell PJ

Nature Communications10(1)DOI: Genomic landscape and chronological reconstruction of driver events in multiple myelomaPubMed: Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Novel Agents in Multiple Myeloma

Szalat R, Munshi NC

The Cancer Journal25(1):45-53DOI: Novel Agents in Multiple MyelomaPubMed: Novel Agents in Multiple Myeloma

Rôle des voies de réparation des dommages de l'ADN dans l'instabilité génomique observée au cours du myélome multipleThesis

Szalat R

Doctoral thesis, Université Sorbonne Paris CitéDOI: Rôle des voies de réparation des dommages de l'ADN dans l'instabilité génomique observée au cours du myélome multiple

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

Leukemia33(1):159-170DOI: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisPubMed: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Genomic patterns of progression in smoldering multiple myeloma

Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

Nature Communications9(1)DOI: Genomic patterns of progression in smoldering multiple myelomaPubMed: Genomic patterns of progression in smoldering multiple myeloma

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

Blood132(6):587-597DOI: Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaPubMed: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Samur MK, Minvielle S, Gulla A, …, Szalat R, …, Munshi NC

Leukemia32(12):2626-2635DOI: Long intergenic non-coding RNAs have an independent impact on survival in multiple myelomaPubMed: Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Fulciniti M, Lin CY, Samur MK, …, Szalat RE, …, Munshi NC

Cell Reports25(13):3693-3705.e6DOI: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple MyelomaPubMed: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Maura F, Petljak M, Lionetti M, …, Szalat R, …, Bolli N

Leukemia32(4):1043-1047DOI: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell linesPubMed: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Expressed fusion gene landscape and its impact in multiple myeloma

Cleynen A, Szalat R, Samur MK, …, Avet-Loiseau H

Nature Communications8(1)DOI: Expressed fusion gene landscape and its impact in multiple myelomaPubMed: Expressed fusion gene landscape and its impact in multiple myeloma

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood129(16):2233-2245DOI: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaPubMed: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Nucleotide excision repair is a potential therapeutic target in multiple myeloma

Szalat R, Samur MK, Fulciniti M, …, Munshi NC

Leukemia32(1):111-119DOI: Nucleotide excision repair is a potential therapeutic target in multiple myelomaPubMed: Nucleotide excision repair is a potential therapeutic target in multiple myeloma

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

Jakubikova J, Cholujova D, Hideshima T, …, Szalat RE, …, Anderson KC

Oncotarget7(47):77326-77341DOI: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applicationsPubMed: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

Corrigendum to “Genomic heterogeneity in multiple myeloma” [Curr. Opin. Genet. Dev. 30 (2015) 56–65]

Szalat R, Munshi NC

Current Opinion in Genetics & Development37:158DOI: Corrigendum to “Genomic heterogeneity in multiple myeloma” [Curr. Opin. Genet. Dev. 30 (2015) 56–65]PubMed: Corrigendum to “Genomic heterogeneity in multiple myeloma” [Curr. Opin. Genet. Dev. 30 (2015) 56–65]

Gene Expression Profiles in Myeloma: Ready for the Real World?

Szalat R, Avet-Loiseau H, Munshi NC

Clinical Cancer Research22(22):5434-5442DOI: Gene Expression Profiles in Myeloma: Ready for the Real World?PubMed: Gene Expression Profiles in Myeloma: Ready for the Real World?

Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Szalat R, Munshi NC

American Society of Clinical Oncology Educational Booke442-e448DOI: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized ApproachesPubMed: Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Genomic heterogeneity in multiple myeloma

Szalat R, Munshi NC

Current Opinion in Genetics & Development30:56-65DOI: Genomic heterogeneity in multiple myelomaPubMed: Genomic heterogeneity in multiple myeloma

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Fouquet G, Hebraud B, Garciaz S, …, Szalat R, …, Leleu X

Journal of Cancer5(3):248-252DOI: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationPubMed: Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Cetin O, Teker G, Szalat RE

Journal of Clinical Oncology44(16_suppl):7567-7567DOI: Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Aktas-Samur A, Fulciniti M, Shah P, …, Szalat RE, …, Munshi NC

Blood144(Supplement 1):1018-1018DOI: Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Srinivasan MD, Culnan J, Hora M, …, Szalat RE, …, Edwards CV

Blood144(Supplement 1):5169-5169DOI: Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

Bodanapu G, Corrigan J, Culnan J, …, Szalat RE, …, Edwards CV

Blood144(Supplement 1):3341-3341DOI: Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems

OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells

Binder M, Szalat R, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur M, Munshi N

Clinical Lymphoma Myeloma and Leukemia22:S13DOI: OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells

Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma

Binder M, Szalat RE, Fulciniti M, Parmigiani G, Samur MK, Munshi NC

Blood138(Supplement 1):2672-2672DOI: Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

Blood138(Supplement 1):545-545DOI: Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma

Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

Clinical Lymphoma Myeloma and Leukemia21:S28DOI: OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Shah P, Aktas-Samur A, Fulciniti M, Szalat R, …, Samur MK

Blood138(Supplement 1):461-461DOI: Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

Bazarbachi AH, Avet-Loiseau H, Hunter ZR, Szalat R, …, Munshi NC

Blood136(Supplement 1):7-8DOI: Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature

High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

Aktas-Samur A, Fulciniti M, Derebail S, Szalat R, …, Munshi NC

Blood136(Supplement 1):2-2DOI: High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Samur MK, Roncador M, Aktas-Samur A, …, Szalat R, …, Munshi NC

Blood136(Supplement 1):4-5DOI: High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma

Alagpulinsa D, Kumar S, Talluri S, …, Szalat R, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e139DOI: E2 ubiquitin conjugase UBE2T contributes to genome maintenance through homologous recombination in multiple myeloma

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Prabhala R, Samur MK, Talluri S, …, Szalat R, …, Munshi NC

Blood134(Supplement_1):1784-1784DOI: Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

Szalat R, Lawlor M, Fulciniti M, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e8-e9DOI: Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma

Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

Perini T, Szalat R, Samur M, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e98-e99DOI: Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Blood134(Supplement_1):3089-3089DOI: Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

Prabhala R, Samur M, Talluri S, …, Szalat R, …, Munshi N

HemaSphere3(S1):246DOI: PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

Aktas Samur A, Minvielle S, Fulciniti M, Szalat R, …, Samur M

HemaSphere3(S1):12DOI: S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Samur MK, Aktas Samur A, Han T, …, Szalat R, …, Munshi NC

Blood134(Supplement_1):3055-3055DOI: The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications

Bolli N, Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Haematologica103(S3):S51-S51

Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

Ott CJ, Szalat R, Lawlor M, …, Munshi N

Blood132(Supplement 1):1313-1313DOI: Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma

DNA repair processes target transcribed region in multiple myeloma

Samur M, Szalat R, Lawlor M, Maura F, Ott C, Bolli N, Anderson K, et al.

HEMASPHERE2(S1):211-211

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Xu Y, Fulciniti M, Ho M, …, Szalat R, …, Munshi N

Blood132(Supplement 1):3176-3176DOI: Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Perini T, Szalat R, Samur MK, …, Munshi N

Blood132(Supplement 1):60-60DOI: Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Samur MK, Chakraborty C, Szalat R, …, Munshi N

Blood132(Supplement 1):190-190DOI: Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

The chronological order of copy number changes in hyperdiploid multiple myeloma patients

Maura F, Bolli N, Dawson K, Angelopoulos N, Szalat R, Martincorena I, et al.

HEMASPHERE2(S1):727-727

The genomic landscape of structural variations and complex events in multiple myeloma

Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Haematologica103(S3):S14-S14

The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

Maura F, Leongamornlert D, Angelopoulos N, …, Szalat R, …, Bolli N

Blood132(Supplement 1):109-109DOI: The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis

A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

Samur M, Gulla A, Fulciniti M, Szalat R, Samur AA, Shamas M, et al.

HAEMATOLOGICA102:495-496

Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma

Ruiz-Heredia Y, Samur MK, Ortiz-Ruiz A, Fernández RA, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):4378 …

Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma

Samur MK, Gulla A, Fulciniti M, …, Szalat R, …, Munshi N

Cancer Research77(13_Supplement):5719-5719DOI: Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma

Bone marrow microenvironment induces genomic instability and enables clonal evolution in multiple myeloma

Perini T, Szalat R, Fulciniti M, Samur MK, Lopez MA, Nanjappa P, Wen K, et al.

Blood130:4408

Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma

Szalat R, Samur MK, Ott CJ, Lawlor M, Epstein C, Abraham BJ, Lin CY, et al.

Blood130:328

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Lin CY, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

Blood130(Suppl_1):64-64DOI: Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma

Prabhala R, Acharya S, Stekla M, Talluri S, Szalat R, Nanjappa P, et al.

Blood130:3049

The apobec mutational activity in multiple myeloma: from diagnosis to cell lines

Maura F, Petljak M, Minvielle S, Szalat R, Lionetti M, Cifola I, Liang W, et al.

haematologica102(suppl. 3):124-124

The genomic landscape of multiple myeloma complex structural variations

Maura F, Bolli N, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):330-330

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Xu Y, Fulciniti M, Samur MK, Szalat R, Ho M, Lopez MA, Li N, Lin J, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):1755 …

A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications

Aktas Samur A, Samur MK, Minvielle S, …, Szalat R, …, Munshi NC

Blood128(22):356-356DOI: A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications

A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis

Bolli N, Biancon G, Gimondi S, Li Y, Sathiaseelan V, Maura F, Carniti C, et al.

HAEMATOLOGICA101(Suppl. 1):160-160

Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

Maura F, Bolli N, Minvielle S, …, Szalat R, …, Munshi N

Blood128(22):116-116DOI: Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Song XL, Szalat R, Talbot A, …, Bories JC

Blood128(22):4462-4462DOI: Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

IMPORTANCE OF SERINE/THREONINE KINASE PAK4 IN MULTIPLE MYELOMA: THERAPEUTIC APPLICATIONS OF A NEW CLASS OF INHIBITORS

Joaquin ML, Mariateresa F, Maria L, Stefania O, Rajya LB, Annamaria G, et al.

HAEMATOLOGICA101:21-21

p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

Fulciniti M, Martinez Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood128(22):3302-3302DOI: p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma

The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

Szalat R, Bolli N, Maura F, …, Munshi NC

Blood128(22):236-236DOI: The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing

Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

Szalat R, Samur MK, Cleynen A, …, Munshi NC

Blood126(23):4187-4187DOI: Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma

The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact

Cleynen A, Szalat R, Samur MK, Parmigiani G, Munshi NC, Avet-Loiseau H

Blood126(23):835-835DOI: The Fusion Gene Landscape in Multiple Myeloma, with Clinical Impact

Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma

Cleynen A, Szalat R, Samur MK, Rashid N, Parmigiani G, Munshi NC, Avet-Loiseau H

Blood124(21):721-721DOI: Frequent Igh Fusion Transcripts with Clinical Impact in Multiple Myeloma

Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)

Szalat R, Dreze M, Samur MK, …, Munshi NC

Blood124(21):2055-2055DOI: Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)

Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Talbot A, Gérard L, Szalat R, …, Arnulf B

Blood122(21):5348-5348DOI: Clinical and Biological Features Of Multiple Myeloma (MM) and Monoclonal Gammopathies In Patients With Human Immunodeficiency Virus (HIV) Infection

Consolidation with VTd Improves the CR Rate Following VTd Induction and Single Autotransplantation in Multiple Myeloma: P-137

XAVIER L, LELEU X, FOUQUET G, HEBRAUD B, ROUSSEL M, et al.

Clinical Lymphoma, Myeloma & Leukemia13:s108-s109

CONSOLIDATION WITH VTD SIGNIFICANTLY IMPROVES THE COMPLETE REMISSION RATE IN MULTIPLE MYELOMA

Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al.

HAEMATOLOGICA98:100-100

Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, Moreau P

Blood122(21):3221-3221DOI: Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd

Xanthogranulome nécrobiotique et myélome multiple

Elfatoiki FZ, Shneider P, Szalat R, Bagot M

Annales de Dermatologie et de Vénéréologie140:S103DOI: Xanthogranulome nécrobiotique et myélome multiple

Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Leleu X, Hebraud B, Fouquet G, …, Szalat R, …, Moreau P

Blood120(21):3096-3096DOI: Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM).

Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Harel S, Bernard S, Chevret S, …, Szalat R, …, Socie G

Blood120(21):2035-2035DOI: Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Arnulf B, Lazareth A, Soulier J, …, Szalat R, …, Fermand JP

Blood120(21):3971-3971DOI: Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

Blood118(21):4501-4501DOI: Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation